CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines…
Articles by Patricia Inácio, PhD
Use of medical marijuana to ease pain is associated with fewer visits to the hospital in people with sickle…
The cannabis company Parallel, which aims to improve quality of life with its products, has launched a 10-year collaboration with…
The National Heart, Lung, and Blood Institute (NHLBI) awarded nearly $1 million to Athena Starlard-Davenport, a professor at…
Bluebird Bio extended a partnership with two divisions of Hitachi Chemical for the long-term development and manufacturing of LentiGlobin, its…
The Phase 2 STRONG-SCD trial evaluating olinciguat as a potential oral therapy for sickle cell disease is…
Global Blood Therapeutics (GBT) is giving $250,000 to support the U.S. sickle cell disease (SCD) community during the…
High blood levels of two pro-inflammatory molecules, called interleukin-6 (IL-6) and interleukin-8 (IL-8), are linked to more frequent…
The Institute for Clinical and Economic Review (ICER) says three recently approved therapies for managing sickle cell disease…
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However,…